Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers

ConclusionIn this pilot study, we show a separation of FTD patients from unaffected individuals based on protein levels in CSF. Further investigation is required to explore the CSF profiles in larger cohorts, but the results presented here has the potential to enable future clinical utilization of these potential biomarkers within FTD.

http://link.springer.com/10.1186/s40035-020-00198-y

Source: Translational Neurodegeneration - June 22, 2020 Category: Neurology Source Type: research